Iron treatment before surgery for colon cancer patients
Preoperative i.v. Iron Substitution in Patients With Colon Carcinoma and Iron-deficiency Anemia
This study tests if giving iron through an IV before surgery can help people with colon cancer who are anemic recover better and have fewer problems after their operation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 514 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Helsinki University Central Hospital Academic / other |
| Locations | 1 site (Espoo, HUS) |
| Trial ID | NCT04653181 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of preoperative intravenous iron substitution in patients with colon cancer who are anemic and iron deficient. It aims to determine whether administering ferric carboxymaltose before surgery can improve postoperative recovery and reduce complications. The study will involve a randomized approach to compare outcomes between those receiving iron treatment and those who do not. The primary focus is on assessing postoperative complications related to the intervention.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old diagnosed with colon cancer and exhibiting preoperative anemia and iron deficiency.
Not a fit: Patients with conditions such as hyperreactivity to Ferinject or hemochromatosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance recovery and reduce complications for colon cancer patients undergoing surgery.
How similar studies have performed: Other studies have shown promising results with intravenous iron treatment in similar patient populations, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age\> 18 years * Dg: Colon ca * The planned measure: the colon resection * Men: Hb \<130, women: Hb \<120 and iron deficiency (elevated TfR, low TrFesat or low ferritin) Exclusion Criteria: * hyperreactivity for Ferinject * haemochromatosis * refusal for participation
Where this trial is running
Espoo, HUS
- Jorvi Hospital — Espoo, Hus, Finland (Recruiting)
Study contacts
- Study coordinator: Suvi K Rasilainen, Md, PhD
- Email: suvi.rasilainen@hus.fi
- Phone: +35894711
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.